Lung cancer trial tests Two-Drug immune attack for Hard-to-Treat tumors

NCT ID NCT06364917

Recruiting now Disease control Sponsor: University of Alabama at Birmingham Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This Phase 2 trial is testing whether using two immune therapy drugs together with chemotherapy works better than one immune drug plus chemo for people with advanced non-small cell lung cancer that lacks the PD-L1 marker. Researchers will track changes in tumor DNA in the blood to see how well the treatment is working. The study aims to enroll 24 adults with stage IV disease who have not received prior therapy.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Pembrolizumab and Carboplatin (chemotherapy plus immune therapy)
What this could lead to: If successful, this could show that adding a second immune therapy to standard chemo-immunotherapy improves outcomes for people with PD-L1 negative lung cancer.
What could go wrong: This is a small Phase 2 trial with only 24 participants, so results may not apply to everyone. Adding a second immune drug may increase side effects without clear benefit.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NON-SMALL CELL LUNG CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

NON-SMALL CELL LUNG CANCER

Contacts and locations

Locations

University of Alabama at Birmingham
RECRUITING

Birmingham, Alabama, 35294, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.